AcquisitionsApr 27, 2026, 04:34 PM
SNSE to become Faeth Therapeutics; $200M PIPE
AI Summary
Sensei Biotherapeutics held its Annual Meeting to approve proposals related to its acquisition of Faeth Therapeutics, Inc. on February 17, 2026. The acquisition involved issuing Series B Preferred Stock convertible into 10,497,098 common shares. Concurrently, Sensei completed a $200 million private placement, issuing 14,440.395 Series B Preferred Stock shares. Post-transactions, Faeth equityholders and PIPE investors will own 40.6% and 54.5% of the common stock, respectively. The company plans to rebrand as Faeth Therapeutics, Inc. and trade under "FTH" upon stockholder and Nasdaq approval.
Key Highlights
- Acquired Faeth Therapeutics on February 17, 2026.
- Issued 10,497.0980 Series B Preferred Stock to Faeth stockholders.
- Completed $200M private placement, issuing 14,440.395 Series B Preferred Stock.
- Faeth equityholders to own ~40.6% of common stock post-conversion.
- PIPE investors to own ~54.5% of common stock post-conversion.
- Proposing to increase authorized common shares from 12.5M to 300M.
- Company name expected to change to Faeth Therapeutics, Inc.
- Ticker symbol expected to change to "FTH".
Price Impact
More from SNSE